BACKGROUND:Neosaxitoxin is a phycotoxin that reversibly blocks the voltage-gated sodium channels at the neuronal level. Its activity results in blocking the axonal conduction, stopping the propagation of the nerve impulse. The objective of the present work was to evaluate neosaxitoxin as a local anesthetic in a human trial. METHODS: The authors conducted a randomized, double-blind, placebo-controlled trial with 10 healthy volunteers. Subcutaneous injections were made in the middle posterior skin of the calf: one leg received 50 microg neosaxitoxin, and the contra-lateral leg received placebo. The anesthetic effect was evaluated using a standardized human sensory and pain model. TSA II Neurosensory Analyzer (Medoc Ltd, Minneapolis, MN) and von Frey technique were used to evaluate five parameters: sensory threshold for warm and cold, pain thresholds for heat and cold, and mechanical touch perception threshold. Measurements were made 0, 1, 3, 6, 9, 12, 16, 24, and 48 h after the injections. RESULTS: For all the patients, effective and complete blocking of the evaluated parameters was obtained. As the blocking began to revert gradually, heat pain was the first to return to normal values after 3 h. Cold pain was the longest sensation abolished, achieving 24 h of blockade. The toxin was undetected in blood and urine samples. No adverse reactions to neosaxitoxin were detected. CONCLUSIONS:Neosaxitoxin showed an effective local anesthetic effect when injected in the subcutaneous plane. The efficacy of a 50-microg dose of neosaxitoxin was shown. This is the first report of neosaxitoxin as a local anesthetic in a human trial.
RCT Entities:
BACKGROUND:Neosaxitoxin is a phycotoxin that reversibly blocks the voltage-gated sodium channels at the neuronal level. Its activity results in blocking the axonal conduction, stopping the propagation of the nerve impulse. The objective of the present work was to evaluate neosaxitoxin as a local anesthetic in a human trial. METHODS: The authors conducted a randomized, double-blind, placebo-controlled trial with 10 healthy volunteers. Subcutaneous injections were made in the middle posterior skin of the calf: one leg received 50 microg neosaxitoxin, and the contra-lateral leg received placebo. The anesthetic effect was evaluated using a standardized human sensory and pain model. TSA II Neurosensory Analyzer (Medoc Ltd, Minneapolis, MN) and von Frey technique were used to evaluate five parameters: sensory threshold for warm and cold, pain thresholds for heat and cold, and mechanical touch perception threshold. Measurements were made 0, 1, 3, 6, 9, 12, 16, 24, and 48 h after the injections. RESULTS: For all the patients, effective and complete blocking of the evaluated parameters was obtained. As the blocking began to revert gradually, heat pain was the first to return to normal values after 3 h. Cold pain was the longest sensation abolished, achieving 24 h of blockade. The toxin was undetected in blood and urine samples. No adverse reactions to neosaxitoxin were detected. CONCLUSIONS:Neosaxitoxin showed an effective local anesthetic effect when injected in the subcutaneous plane. The efficacy of a 50-microg dose of neosaxitoxin was shown. This is the first report of neosaxitoxin as a local anesthetic in a human trial.
Authors: James R Walker; Paul A Novick; William H Parsons; Malcolm McGregor; Jeff Zablocki; Vijay S Pande; J Du Bois Journal: Proc Natl Acad Sci U S A Date: 2012-10-17 Impact factor: 11.205
Authors: Kathleen Cullion; Claudia M Santamaria; Changyou Zhan; David Zurakowski; Tao Sun; Grant L Pemberton; Nathan J McDannold; Daniel S Kohane Journal: J Control Release Date: 2018-02-20 Impact factor: 9.776
Authors: Maria Carmen Louzao; Natalia Vilariño; Carmen Vale; Celia Costas; Alejandro Cao; Sandra Raposo-Garcia; Mercedes R Vieytes; Luis M Botana Journal: Mar Drugs Date: 2022-03-08 Impact factor: 5.118
Authors: Livia S Eberlin; John V Mulcahy; Alexander Tzabazis; Jialing Zhang; Huwei Liu; Matthew M Logan; Heather J Roberts; Gordon K Lee; David C Yeomans; Justin Du Bois; Richard N Zare Journal: J Am Chem Soc Date: 2014-04-17 Impact factor: 15.419